News

Guerbet Announces CE Mark for Vectorio®, An Innovative Medical Device for cTACE Procedures

14.09.2017 18:00

Vectorio® will be presented at the upcoming radiology congresses

Villepinte (France), September 14, 2017 (6:00 PM CEST) – Guerbet (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, announced today that it has obtained the CE mark for its innovative conventional Trans-Arterial Chemo-Embolization (cTACE) mixing and injection system, Vectorio®

Designed in collaboration with interventional radiologists worldwide, Vectorio® is a unique set of Lipiodol® resistant medical devices including syringes, patented stopcock and sampling devices. Vectorio® is dedicated for mixing and delivering Lipiodol® Ultra Fluid & anticancer drugs during cTACE procedure in adults with known, intermediate-stage hepatocellular carcinoma (HCC).

HCC is the most common primary liver cancer and is the second biggest cause of death due to cancer worldwide (1)

This medical device offers multiple advantages for healthcare professionals:

  • 24 hours Lipiodol® resistance.  
  • Patented 3-way stopcock with 4 connections offering possibility of “On-table mixing” (interventional radiologists have the possibility of remixing without disconnection from the micro-catheter, thus maximizing the safety during the intervention).
  • Unique ready-to-use set: all devices in one set.
  • User-friendly: Ergonomic and quick device set-up, improving cTACE procedures for physicians.

"Vectorio® has been developed in collaboration with international interventional radiologists to match their medical needs for accurate, user-friendly and safe solution during cTACE procedures. The development of these image-guided procedures is a top priority for Guerbet’s Interventional franchise. We are committed to enhance liver cancer patients’ prognosis and quality of life worldwide" said Yves L’Epine, CEO of Guerbet. 

Vectorio® Mixing & Injection system: Description

Designed and manufactured in France, Vectorio®‘s commercial launch will start this fall in European countries, where Lipiodol® Ultra Fluid is registered for cTACE (2). Vectorio® registration program is also planned in other countries where cTACE is indicated (2) for Lipiodol® Ultra Fluid.

Guerbet teams will present Vectorio® in specialized international congresses in the upcoming weeks, where experts will carry out interactive demonstrations (CIRSE, JFR…).

Read the press release

 

References

(1) WHO – Globocan 2012 (IARC) Section of Cancer Surveillance (9/7/2014). 
(2) Countries in which cTACE indication is registered: France, Japan, South Korea, Austria, Peru, Turkey, Hungary, Czech Republic, Mongolia, Argentina, The Netherlands, Vietnam, Thaïland, Mexico & Brazil.